Search

everythinglearnresearchcommunity

for

Search:↓

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

ERG increases SOX9, promoting prostate cancer growth and invasion.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Dutasteride may help shrink prostate cancer tumors.

Androgen receptors help prostate cancer cells grow and resist drugs.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Finasteride does not prevent bladder cancer.

Minoxidil increases calcium levels and kills prostate cancer cells independently of calcium.

Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

Overexpressing SSAT enzyme reduces prostate tumor growth in mice.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.

Finasteride is effective for treating BPH but not recommended for prostate cancer prevention.

Starting finasteride at age 65 and continuing until age 80 is the most cost-effective strategy for prostate cancer prevention.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.